Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?

Samy Suissa, Deborah Assayag

Source: Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020
Journal Issue: March
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Samy Suissa, Deborah Assayag. Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?. Eur Respir J, 57 (3) 2004562; 10.1183/13993003.04562-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

liberty jasy - 04.07.2022 04:29
My husband had ALS, first symptom was weakness in his fingers, one day, we had a dream life with early retirement and then, when we went to find out about the weakness, our whole world almost changed. There are so many things that can be said about the suffering and frustration of people with ALS, we look back now and realize in many ways how lucky we were to found Dr. Timothy herbal cure that was able to get rid of my husband ALS disease totally, we had time to enjoy life and above all we all had time to also share this great testimony , many people lose loved ones without closure. I can’t imagine going thru all that you or your family had to live with daily, do not hesitate to contact https://5dc41d5b6d60d.site123.me or email goodhealthherbalfoundation@yahoo.com for ALS cure.

Teresa Lawrence - 21.12.2021 10:28
It’s difficult not knowing what the next day will bring. To anyone who’s just been diagnosed with IPF, or another long-term lung condition, I’d say live life to the full and take all the help you can get. It can be difficult to talk to your family and friends about what you’re going through, but it’s important to make sure they understand what’s happening and how you’re feeling. I was cured naturally with the use of Dr Gomez Sims RSO Cannabis Oil, within a period of 3 weeks, I was recovering, It’s also crucial to learn as much as you can about your diagnosis. Seek options. Find out about what’s out there that could help. Contact Dr Odia via email:( drodiaherbalistcenter@gmail.com ) or ( WhatsApp +17278553511 ) or visit www.facebook.com/DrOdiathenaturopathic/
You must Login to comment this presentation.


Related content which might interest you:
Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
Source: Eur Respir J, 51 (1) 1702420; 10.1183/13993003.02420-2017
Year: 2018



Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial “impact” beyond any expectation
Source: Eur Respir J, 57 (3) 2003111; 10.1183/13993003.03111-2020
Year: 2021



Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Historical eye on idiopathic pulmonary fibrosis: redefining the mortality scenario.
Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Year: 2020




Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis?  Real- world results from the EMPIRE registry.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017

Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015


Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries.
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Insights into idiopathic pulmonary fibrosis in the real world
Source: Eur Respir J 2015; 46: 16-18
Year: 2015


Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry
Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Year: 2019



Idiopathic pulmonary fibrosis: time for greater expectations?
Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018
Year: 2018



Idiopathic pulmonary fibrosis mortality in the United States: is there any evidence of occupational risk?
Source: Eur Respir J 2005; 26: Suppl. 49, 702s
Year: 2005

Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?
Source: Eur Respir Rev 2011; 20: 201-207
Year: 2011



A global registry for idiopathic pulmonary fibrosis: the time is now
Source: Eur Respir J 2014; 44: 273-276
Year: 2014


The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Year: 2020


Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020


Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012


Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
Source: Eur Respir Rev, 26 (145) 170071; 10.1183/16000617.0071-2017
Year: 2017